文献速递烧伤创面修复

厄他环素治疗烧伤患者碳青霉烯耐药不动杆菌感染的回顾性病例对照研究

A Retrospective Case-Control Study of Eravacycline for the Treatment of Carbapenem-Resistant Acinetobacter Infections in Patients With Burn Injuries.
PubMed 文献 · J Burn Care Res · 2024-01-01

这项回顾性病例对照研究比较了厄他环素与黏菌素甲磺酸钠治疗烧伤患者碳青霉烯耐药鲍曼不动杆菌感染的结果。厄他环素与 favorable 复合结局无显著关联(OR 2.066,95%CI 0.456-9.361,P=0.347),黏菌素组新发急性肾损伤的比值比接近9倍(OR 8.816,95%CI 0.911-85.308,P=0.06),两组死亡率无差异。

要点

  • 厄他环素与黏菌素治疗碳青霉烯耐药鲍曼不动杆菌感染的 favorable 复合结局无显著差异(OR 2.066,P=0.347)。
  • 黏菌素组新发急性肾损伤的比值比接近9倍(OR 8.816,P=0.06),未达统计学显著。
  • 厄他环素组不良事件不常见,两组死亡率无差异。

核心结论

  • 厄他环素与黏菌素甲磺酸钠相比,与 favorable 复合结局的关联无显著差异(OR 2.066,95%CI 0.456-9.361,P=0.347)。
  • 黏菌素组新发急性肾损伤的比值比接近9倍(OR 8.816,95%CI 0.911-85.308,P=0.06),未达统计学显著。
  • 厄他环素组不良事件不常见,两组死亡率无差异。

研究设计与样本

  • 回顾性病例对照研究,纳入2019年5月1日至2022年7月31日期间在美国烧伤协会认证烧伤中心收治并接受厄他环素的烧伤患者,按%TBSA、年龄和CRAB以4:1随机匹配至同一中心2009年3月1日至2014年3月31日期间接受黏菌素甲磺酸钠治疗的历史队列。

主要发现

  • 厄他环素组与黏菌素组 favorable 复合结局的OR为2.066(95%CI 0.456-9.361,P=0.347)。
  • 黏菌素组新发急性肾损伤的OR为8.816(95%CI 0.911-85.308,P=0.06),未达统计学显著。
  • 厄他环素组不良事件不常见,两组死亡率无差异。

关键数值与推荐

  • favorable 复合结局定义为30天生存、完成疗程、14天无复发且无急性肾损伤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thermal injuries lead to a deficiency in one's natural, protective barrier, resulting in increased susceptibility to pathogens, and often require multiple courses of broad-spectrum antibiotics. Eravacycline (ERA) has shown adequate in vitro activity against multiple multi-drug resistant (MDR) pathogens including Acinetobacter sp. Due to the increasing prevalence of MDR bacteria and the heightened susceptibility of patients with burns to infection, studies are needed to examine the clinical effect of eravacycline in this population. The objective of this retrospective, case-control study was to compare the outcomes of patients with thermal injuries treated with eravacycline versus a matched control for carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients with thermal injury admitted to an American Burn Associated-verified burn center from May 1, 2019 to July 31, 2022, who received eravacycline, were randomly matched 4:1 to a historical cohort using a previously established, de-identified dataset of patients treated with colistimethate sodium (CMS) in the same burn center (March 1, 2009 to March 31, 2014), based on % total body surface area (%TBSA), age, and CRAB. A composite favorable outcome was defined as 30-day survival, completion of the course, lack of 14-day recurrence, and lack of acute kidney injury (AKI). Treatment with eravacycline over CMS was not more or less likely to be associated with a favorable response [odds ratio (95% confidence interval), 2.066 (0.456-9.361), P = .347]. Patients treated with CMS had nearly 9-fold higher odds of new-onset AKI versus ERA [8.816 (0.911-85.308), P = .06]. Adverse events were uncommon in the ERA group. There was no difference in mortality.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Alexander C, Hill D. A Retrospective Case-Control Study of Eravacycline for the Treatment of Carbapenem-Resistant Acinetobacter Infections in Patients With Burn Injuries. J Burn Care Res. 2024. PMID: 37971422. doi:10.1093/jbcr/irad183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。